SimpsonEL, BieberT, Guttman-YasskyE, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2016; 375(24):2335–2348.
2.
BlauveltA, de Bruin-WellerM, GooderhamM, et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 2017; 389(10086):2287–2303.
3.
WollenbergA, AriensL, ThurauS, et al.Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. J Allergy Clin Immunol Pract, 2018; 6(5):1778–1780.e1.
4.
MenniniM, DahdahL, FiocchiA. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2017; 376(11):1090.
5.
HossainP, KonstantopoulosA. Blepharitis: remains a diagnostic enigma. A role for tea tree oil shampoo? Eye, 2015; 29(12):1520–1521.
6.
GlatzM, BosshardP, Schmid-GrendelmeierP. The role of fungi in atopic dermatitis. Immunol Allergy Clin North Am, 2017; 37(1):63–74.
AftabBT, DobromilskayaI, LiuJO, et al.Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res, 2011; 71(21):6764–6772.
9.
NelsonME, MidgleyG, BlatchfordNR. Ketoconazole in the treatment of blepharitis. Eye, 1990; 4(1):151.
